LadRx Corporation
11726 San Vicente Boulevard
Suite 650
Los Angeles
California
90049
United States
Tel: 310-826-5648
Fax: 310-826-6139
Website: http://www.cytrx.com/
518 articles about LadRx Corporation
-
CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress
3/25/2021
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the fourth quarter and fiscal year ended December 31, 2020. (NASDAQ: IBRX) (“ImmunityBio”) an
-
CytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
3/8/2021
Orphazyme Announces the Global Brand Name for Arimoclomol – MIPLYFFA – Ahead of Prospective FDA and EMA Approvals Expanded its Early Access Program for NPC in the U.S. and Europe as Well as Expectation of European Regulatory Decision by Q4 2021
-
CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
3/4/2021
CytRx Corporation has announced the appointment of Christophe Bourdon as its new Chief Executive Officer, effective as of April 1, 2021.
-
CytRx to Participate in Upcoming Investor Conferences
3/3/2021
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to participate in the following upcoming conferences:
-
CytRx is Added to the LD Micro Index
2/11/2021
CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, announced that it is now a part of the LD Micro Index.
-
CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C
12/31/2020
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today provided an update on the U.S. Food and Drug Administration’s (“FDA”) review of Orphazyme A/S’s (NASDAQ: ORPH) (“Orphazyme”) New Drug Application (“NDA”) for arimoclomol to treat Niemann-Pick Disease Type C (“NPC”).
-
CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
11/11/2020
Applauds Orphazyme’s Efforts to Pursue Approval in Europe for Arimoclomol in the Treatment of Niemann-Pick Disease Type C Notes That Arimoclomol for Niemann-Pick Disease Type C is Under the FDA’s Priority Review With a Target Action Date of March 17, 2021
-
CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment
10/13/2020
Third-Line Cohort Added to Phase 2 Pancreatic Cancer Trial for Combination Immunotherapy That Includes Aldoxorubicin, ImmunityBio’s N-803 and NantKwest’s PD-L1 t-haNK Three Trial Sites in California and South Dakota Will Initially Enroll 298 Patients Across the Cohorts, With 40 Patients Already Enrolled or Being Evaluated LOS ANGELES--( BUSINESS WIRE )-- CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceuti
-
CytRx Issues Statement Regarding Orphazyme’s Global Offering
9/30/2020
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) (“Orphazyme”) on the September 29, 2020 pricing of its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent priv
-
CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C
9/17/2020
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority
-
CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation
9/3/2020
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative
-
CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities
8/24/2020
Accelerates Plans to Enhance its Board Composition by Committing to Add a New Independent Director Following a Professionally-Managed Search Process that Includes Stockholder Input Augments Existing Cost Reduction Efforts by Capping Management Compensation and Director Fees at Their Current Levels For the Next Two Years Reaches Agreement with Stockholder, Resulting in a Withdrawal of his Nomination Notice and Certain Other Demands Relating t
-
CytRx’s Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign
8/13/2020
CytRx Corporation (OTCQB: CYTR), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has mailed a letter to stockholders in connection with the Company’s Annual Meeting of Stockholders that is scheduled for September 3, 2020.
-
CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders
8/10/2020
Urges Stockholders to Sign, Date and Promptly Return the BLUE Proxy Card to Support CytRx's Highly-Experienced Directors at the September 3rd Annual Meeting
-
CytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
7/21/2020
Orphazyme expects to submit MAA for arimoclomol for NPC to European Medicines Agency in the second half of 2020 Arimoclomol progressing through registrational trials in two additional indications - ALS and sIBM
-
CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with The Michael J. Fox Foundation on Parkinson's Disease Research
7/20/2020
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that
-
CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease
6/29/2020
Arimoclomol demonstrated a marked and clinically meaningful dose-dependent reduction in liver and spleen size Data supports Orphazyme's intention to proceed with pivotal stage clinical development in Gaucher disease [29-June-2020] LOS ANGELES , June 29, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company
-
CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
6/1/2020
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have initiated the submission of t
-
CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
5/26/2020
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development of arimoclomol for the t
-
CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin
5/21/2020
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88).